This case series focuses on Theranos Inc. (Theranos), a health care technology start-up founded by Elizabeth Holmes in 2003. Theranos focused on developing a revolutionary blood-testing technology that was supposed to be able to detect diseases using only a few drops of blood. Once valued at US$10 billion, the company never demonstrated its alleged technological breakthrough, and Holmes was eventually charged by the Securities and Exchange Commission for fraud and deceit. In 2018, Theranos was forced to shut down its operations, and in January 2022, Holmes was found guilty of three counts of wire fraud and one count of conspiracy to commit wire fraud. The case series explores Theranos’s history, as well as the role of overconfidence bias in Theranos’s downfall.
This case series focuses on Theranos Inc. (Theranos), a health care technology start-up founded by Elizabeth Holmes in 2003. Theranos focused on developing a revolutionary blood-testing technology that was supposed to be able to detect diseases using only a few drops of blood. Once valued at US$10 billion, the company never demonstrated its alleged technological breakthrough, and Holmes was eventually charged by the Securities and Exchange Commission for fraud and deceit. In 2018, Theranos was forced to shut down its operations, and in January 2022, Holmes was found guilty of three counts of wire fraud and one count of conspiracy to commit wire fraud. The case series explores Theranos’s history, as well as the role of overconfidence bias in Theranos’s downfall.
This case series focuses on Theranos Inc. (Theranos), a health care technology start-up founded by Elizabeth Holmes in 2003. Theranos focused on developing a revolutionary blood-testing technology that was supposed to be able to detect diseases using only a few drops of blood. Once valued at US$10 billion, the company never demonstrated its alleged technological breakthrough, and Holmes was eventually charged by the Securities and Exchange Commission for fraud and deceit. In 2018, Theranos was forced to shut down its operations, and in January 2022, Holmes was found guilty of three counts of wire fraud and one count of conspiracy to commit wire fraud. The case series explores Theranos’s history, as well as the role of overconfidence bias in Theranos’s downfall.
In 2021, the investment bank Credit Suisse Group AG lost an estimated US$6.4 billion from exposure to two hedge fund implosions that occurred within a month. Archegos Capital Management lost US$4.7 billion and Greensill Capital lost US$1.7 billion. Various arrangements between Credit Suisse Group AG and Archegos Capital Management, as well as structural factors at Credit Suisse Group AG, may have contributed to the bank having a higher level of exposure to these collapses than its industry peers. Underlying these miscues were recent changes in leadership, strategy, and tone at Credit Suisse Group AG. All three of these changes appeared to have collectively impaired the skepticism and voice exercised by its risk management group. In July 2021, Credit Suisse Group AG replaced its chief risk officer in an attempt to reshuffle its risk and compliance leadership. The task of the new chief risk officer was to reshape Credit Suisse Group AG’s risk management framework and internal controls, from the top to the bottom.